Table I.
Asthma and healthy group patient demographics
| Characteristic | Asthma (n = 92) | Healthy (n = 44) | P value |
|---|---|---|---|
| Age (y) | 23.00 (21.00-27.00) | 38.00 (29.00-50.75) | <.0001 |
| Sex (male:female) | 39:53 | 14:30 | .26 |
| BMI (kg/m2) | 24.15 (21.80-27.05) | 24.60 (22.30-28.28) | .34 |
| FEV1 (% predicted) | 95.50 (87.00-103.00) | 103.00 (96.25-114.00) | <.0001 |
| FVC (% predicted) | 103.00 (95.00-109.00) | 104.50 (98.25-118.00) | .05 |
| Age of onset (y) | 7.50 (4.25-14.75) | ||
| Serum eosinophils (× 109/L) | 0.21 (0.13-0.32) | ||
| Serum total IgE (kU/L) | 200.00 (61.50-487.50) | ||
| Feno (ppb) | 36.00 (22.00-86.75) | ||
| Atopic, % | 80.43 | ||
| Methacholine PC20 (mg/mL) | 0.97 (0.26-3.21) | ||
| SABA use, % | 100.00 | ||
| ICS use, % | 34.78 | ||
| ICS/LABA combination use, % | 17.39 | ||
| Daily ICS dose (μg of FP equivalent) | 50.00 (0.00-237.50) | ||
| Steroid naive, % | 48.91 | ||
| ACQ7 category, % | |||
| Well controlled | 53.26 | ||
| Partly controlled | 35.87 | ||
| Poorly controlled | 10.87 | ||
| GINA category, % | |||
| Well controlled | 53.26 | ||
| Partly controlled | 46.74 | ||
ACQ7, 7-Item Asthma Control Questionnaire; BMI, body mass index; FP, fluticasone proprionate; FVC, forced vital capacity; Feno, fraction of exhaled nitric oxide; GINA, Global Initiative for Asthma; LABA, long-acting beta-agonist; SABA, short-acting beta-agonist.
Data quoted as median and interquartile ranges (significance: P < .05).